Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
about
Brain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementationCreatine for Parkinson's diseaseCreatine for Parkinson's diseaseEffect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseMitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration.Creatine protects against mitochondrial dysfunction associated with HIV-1 Tat-induced neuronal injury.Death in the substantia nigra: a motor tragedy.Mitochondrial approaches for neuroprotectionThe biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's diseaseCreatine in mouse models of neurodegeneration and aging.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Creatine for neuroprotection in neurodegenerative disease: end of story?Beyond muscles: The untapped potential of creatine.Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation.PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.
P2860
Q21245420-8124DE1E-8303-4805-9DEE-2BA1FC0E7621Q24193947-BF96B941-F411-4599-8928-CED3A375E721Q24203799-A56437E3-927B-44DE-9427-55F9A3AC5B0AQ30407589-5DCA82C5-B6DF-478A-A9B9-E6D1BB891180Q30484548-0335EEDF-2142-4D28-912D-85102553CC9CQ33644322-3B7F426C-F3F1-4C8C-A689-F7F9FDE5633DQ33837238-C44BCB4B-FDA5-4AE8-A629-6B259AD22956Q34043950-02EB229A-20C0-4854-88FF-9B60410B7D79Q34460675-B7DDEDA5-3E4E-4297-815D-6C82DBEDF4A4Q34933261-856E27FE-CB90-4C8E-ACB6-E0AD4EC85B8EQ35215063-301BB8FF-BA8E-4899-80C4-CE7D478D5940Q36847262-9BDB51DD-5960-4AD7-B16E-C1DCF249B0A8Q37348590-5237D824-5545-40B4-9643-846E5E3C1F5CQ37845675-454BD10F-522D-468F-8CB0-4B0ED064DDACQ37851389-525625E6-9DDD-4B77-8775-FB5C072D8F61Q38202314-638B3072-92BD-4E8B-901A-8E5C2A6C5FC7Q38691246-A312C9A6-8DBA-4935-8F8F-24543AA4DC0AQ38700215-90154AEA-7770-4403-8A17-ADE34E932A80Q38974344-AC5252A1-DA1D-4A41-9DA3-0B1CE485E263Q41769727-2902830D-2E87-4F42-B17B-A0929E63D271Q42908536-3AEB4367-151A-42B0-9BC7-AD1D151B9139
P2860
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Additive neuroprotective effec ...... model of Parkinson's disease.
@en
Additive neuroprotective effec ...... model of Parkinson's disease.
@nl
type
label
Additive neuroprotective effec ...... model of Parkinson's disease.
@en
Additive neuroprotective effec ...... model of Parkinson's disease.
@nl
prefLabel
Additive neuroprotective effec ...... model of Parkinson's disease.
@en
Additive neuroprotective effec ...... model of Parkinson's disease.
@nl
P2093
P356
P1476
Additive neuroprotective effec ...... e model of Parkinson's disease
@en
P2093
Gabrielle Gardian
Lichuan Yang
M Flint Beal
Noel Y Calingasan
P2888
P304
P356
10.1385/JMN:21:3:191
P577
2003-01-01T00:00:00Z
P6179
1019226286